Role of fatty acids in the pathogenesis of obesity and fatty liver: Impact of bariatric surgery

Seminars in Liver Disease

Volumn 28, Issue 4, 2008, Pages 407-426

  Verna, Elizabeth C ^a   Berk, Paul D ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Hepatic steatosis; NAFLD; NASH; Nonalcoholic fatty liver disease; Obesity; Steatohepatitis; Type 2 diabetes mellitus

Indexed keywords

GHRELIN; LEPTIN; LONG CHAIN FATTY ACID; OLEIC ACID; PEPTIDE YY;

BARIATRIC SURGERY; DISEASE COURSE; FATTY LIVER; FOLLOW UP; GASTRECTOMY; GASTRIC BANDING; HUMAN; JEJUNOILEAL BYPASS; LIPID STORAGE; LIVER BIOPSY; LIVER FAILURE; LIVER FIBROSIS; LIVER HISTOLOGY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION;

ABDOMINAL FAT; ADIPOCYTES; ANIMALS; BARIATRIC SURGERY; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FATTY ACIDS; FATTY LIVER; GASTROINTESTINAL HORMONES; HUMANS; INSULIN RESISTANCE; LEPTIN; LIPOLYSIS; LIVER; METABOLIC SYNDROME X; OBESITY; OBESITY, MORBID;

EID: 56649115813     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0028-1091985     Document Type: Review

References (210)

1. The Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity - 2001. Washington, DC: Goverment Printing Office, U.S. Department of Health and Human Services; 2001
2. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002;346(8):591-602
3. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288(14):1723-1727
4. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology 2007;132(6):2087-2102
5. State-specific prevalence of obesity among adults - United States, 2005. MMWR Morb Mortal Wkly Rep 2006;55(36):985-988
6. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12(5):1106-1110
7. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98(5):960-967
8. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124(1):71-79
9. Ruhl CE, Everhart JE. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis 2004;8(3):501-519
10. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40(6):1387-1395
11. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40(suppl 1):S5-S10
12. Kopelman PG. Obesity as a medical problem. Nature 2000;404(6778):635-643
13. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295(13):1549-1555
14. Ogden CL, McDowell MA, Flegal KM. Obesity among adults in the United States: no change since 2003-2004. NCHS Data Brief #1. Hyattsville, MD: National Center for Health Statistics; 2007
15. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005;366(9499):1784-1793
16. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41(6):1313-1321
17. Bondini S, Kleiner DE, Goodman ZD, Gramlich T, Younossi ZM. Pathologic assessment of non-alcoholic fatty liver disease. Clin Liver Dis 2007;11(1):17-23
18. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 2007;128(5):837-847
19. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001;21(1):3-16
20. Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol 2004;35(9):1070-1082
21. Brunt EM. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Semin Diagn Pathol 2005;22(4):330-338
22. Thung SN, Gerber M. Alcoholic hepatitis vs nonalcoholic steatohepatitis. In: Thung SN, Gerber MA, eds. Differential Diagnosis in Pathology: Liver Disorders. New York: Igaku-Shoin; 1995:24-36
23. Pinto HC, Baptista A, Camilo ME, Valente A, Saragoca A, de Moura MC. Nonalcoholic steatohepatitis: clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996;41(1):172-179
24. Gramlich T, Kleiner DE, McCullough AJ, Matteoni CA, Boparai N, Younossi ZM. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol 2004;35(2):196-199
25. Leclercq IA, Horsmans Y. Cell biology of NASH: fibrosis and cell proliferation. In: Farrell GC, George J, Hall P de la M, McCullough AK, eds. Fatty Liver Disease: NASH and Related Disorders. Oxford: Blackwell; 2005:143-158
26. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11(1):74-80
27. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995;22(6):1714-1719
28. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116(6):1413-1419
29. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004;40(4):820-826
30. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42(1):132-138
31. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129(1):113-121
32. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007;102(2):399-408
33. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003;289(22):3000-3004
34. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of nonalcoholic fatty liver disease. J Hepatol 2004;40(4):578-584
35. Caldwell SHHA. The clinical outcome of NAFLD including cryptogenic cirrhosis. In: Farrell GC, George J, Hall P de la M, McCullough AK, eds. Fatty Liver Disease: NASH and Related Disorders. Oxford: Blackwell; 2005:168-180
36. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43(suppl 1):S99-S112
37. Charlton M, Kasparova P, Weston S, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001;7(7):608-614
38. Burke A, Lucey MR. Non-alcoholic fatty liver disease, nonalcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 2004;4(5):686-693
39. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004;2(12):1048-1058
40. Bugianesi E, Marzocchi R, Villanova N, Marchesini G. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. Best Pract Res Clin Gastroenterol 2004;18(6):1105-1116
41. Rafiq N, Younossi ZM. Effects of weight loss on nonalcoholic fatty liver disease. Semin Liver Dis 2008;28:427-433
42. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355(22):2297-2307
43. Ghali P, Lindor KD. Hepatotoxicity of drugs used for treatment of obesity and its comorbidities. Semin Liver Dis 2004;24(4):389-397
44. Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 2005;330(6):326-335
45. Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Managing nonalcoholic fatty liver disease: recommendations for family physicians. Can Fam Physician 2007;53(5):857-863
46. Kadayifci A, Merriman RB, Bass NM. Medical treatment of non-alcoholic steatohepatitis. Clin Liver Dis 2007;11(1):119-140 ix
47. Clark JM. Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol 2006;40(suppl 1):S39-S43
48. Stremmel W, Berk PD. Hepatocellular influx of [14C]oleate reflects membrane transport rather than intracellular metabolism or binding. Proc Natl Acad Sci U S A 1986;83(10):3086-3090
49. Schwieterman W, Sorrentino D, Potter BJ, et al. Uptake of oleate by isolated rat adipocytes is mediated by a 40-kDa plasma membrane fatty acid binding protein closely related to that in liver and gut. Proc Natl Acad Sci U S A 1988;85(2):359-363
50. Sorrentino D, Stump D, Potter BJ, et al. Oleate uptake by cardiac myocytes is carrier mediated and involves a 40-kD plasma membrane fatty acid binding protein similar to that in liver, adipose tissue, and gut. J Clin Invest 1988;82(3):928-935
51. Stremmel W. Uptake of fatty acids by jejunal mucosal cells is mediated by a fatty acid binding membrane protein. J Clin Invest 1988;82(6):2001-2010
52. Nunes RM, Isola LM, Sorrentino D, Berk PD. Oleate uptake by isolated hepatocytes consists of two components, each driven by the unbound oleate concentration. In: Proceedings of the 3rd International Congress, Mathematical Modelling of Liver Excretory Process. Tokyo: Juntendo University Press; 1990:312-316
53. Stump DD, Nunes RM, Sorrentino D, Isola LM, Berk PD. Characteristics of oleate binding to liver plasma membranes and its uptake by isolated hepatocytes. J Hepatol 1992;16(3):304-315
54. Berk PD, Stump DD. Mechanisms of cellular uptake of long chain free fatty acids. Mol Cell Biochem 1999;192 (1-2):17-31
55. Stump DD, Fan X, Berk PD. Oleic acid uptake and binding by rat adipocytes define dual pathways for cellular fatty acid uptake. J Lipid Res 2001;42(4):509-520
56. Stoll GH, Voges R, Gerok W, Kurz G. Synthesis of a metabolically stable modified long-chain fatty acid salt and its photolabile derivative. J Lipid Res 1991;32(5):843-857
57. Schmider W, Fahr A, Blum HE, Kurz G. Transport of heptafluorostearate across model membranes: membrane transport of long-chain fatty acid anions I. J Lipid Res 2000;41(5):775-787
58. Abumrad NA, Perkins RC, Park JH, Park CR. Mechanism of long chain fatty acid permeation in the isolated adipocyte. J Biol Chem 1981;256(17):9183-9191
59. Abumrad NA, Park JH, Park CR. Permeation of long-chain fatty acid into adipocytes: kinetics, specificity, and evidence for involvement of a membrane protein. J Biol Chem 1984;259(14):8945-8953
60. Weisiger RA, Fitz JG, Scharschmidt BF. Hepatic oleate uptake: electrochemical driving forces in intact rat liver. J Clin Invest 1989;83(2):411-420
61. Glatz JF, van Nieuwenhoven FA, Luiken JJ, Schaap FG, van der Vusse GJ. Role of membrane-associated and cytoplasmic fatty acid-binding proteins in cellular fatty acid metabolism. Prostaglandins Leukot Essent Fatty Acids 1997;57(4-5):373-378
62. Luiken JJ, Turcotte LP, Bonen A. Protein-mediated palmitate uptake and expression of fatty acid transport proteins in heart giant vesicles. J Lipid Res 1999;40(6):1007-1016
63. Luiken JJ, Glatz JF, Bonen A. Fatty acid transport proteins facilitate fatty acid uptake in skeletal muscle. Can J Appl Physiol 2000;25(5):333-352
64. Kampf JP, Kleinfeld AM. Fatty acid transport in adipocytes monitored by imaging intracellular free fatty acid levels. J Biol Chem 2004;279(34):35775- 35780
65. Kleinfeld AM, Kampf JP, Lechene C. Transport of 13C-oleate in adipocytes measured using multi imaging mass spectrometry. J Am Soc Mass Spectrom 2004;15(11):1572-1580
66. Stremmel W, Strohmeyer G, Borchard F, Kochwa S, Berk PD. Isolation and partial characterization of a fatty acid binding protein in rat liver plasma membranes. Proc Natl Acad Sci U S A 1985;82(1):4-8
67. Bradbury MW, Berk PD. Cellular uptake of long chain free fatty acids: the structure and function of plasma membrane fatty acid binding protein. Adv Mol Cell Biol 2004;33:47-81
68. Berk PD, Wada H, Horio Y, et al. Plasma membrane fatty acid-binding protein and mitochondrial glutamic-oxaloacetic transaminase of rat liver are related. Proc Natl Acad Sci U S A 1990;87(9):3484-3488
69. Stump DD, Zhou SL, Berk PD. Comparison of plasma membrane FABP and mitochondrial isoform of aspartate aminotransferase from rat liver. Am J Physiol 1993;265 (5 Pt 1):G894-G902
70. Abumrad NA, el-Maghrabi MR, Amri EZ, Lopez E, Grimaldi PA. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation: homology with human CD36. J Biol Chem 1993;268(24):17665-17668
71. Schaffer JE, Lodish HF. Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein. Cell 1994;79(3):427-436
72. Hirsch D, Stahl A, Lodish HF. A family of fatty acid transporters conserved from mycobacterium to man. Proc Natl Acad Sci U S A 1998;95(15):8625-8629
73. Stahl A, Gimeno RE, Tartaglia LA, Lodish HF. Fatty acid transport proteins: a current view of a growing family. Trends Endocrinol Metab 2001;12(6):266-273
74. Trigatti BL, Anderson RG, Gerber GE. Identification of caveolin-1 as a fatty acid binding protein. Biochem Biophys Res Commun 1999;255(1):34-39
75. Pohl J, Ring A, Stremmel W. Uptake of long-chain fatty acids in HepG2 cells involves caveolae: analysis of a novel pathway. J Lipid Res 2002;43(9):1390-1399
76. Kampf JP, Parmley D, Kleinfeld AM. Free fatty acid transport across adipocytes is mediated by an unknown membrane protein pump. Am J Physiol Endocrinol Metab 2007;293(5):E1207-E1214
77. Berk PD, Zhou SL, Kiang CL, Stump D, Bradbury M, Isola LM. Uptake of long chain free fatty acids is selectively up-regulated in adipocytes of Zucker rats with genetic obesity and non-insulin-dependent diabetes mellitus. J Biol Chem 1997;272(13):8830-8835
78. Berk PD, Zhou SL, Bradbury M, Stump D, Kiang CL, Isola LM. Regulated membrane transport of free fatty acids in adipocytes: role in obesity and non-insulin dependent diabetes mellitus. Trans Am Clin Climatol Assoc 1997;108:26-40; discussion 41-43
79. Berk PD, Zhou S, Kiang C, Stump DD, Fan X, Bradbury MW. Selective up-regulation of fatty acid uptake by adipocytes characterizes both genetic and diet-induced obesity in rodents. J Biol Chem 1999;274(40):28626-28631
80. Petrescu O, Fan X, Gentileschi P, et al. Long-chain fatty acid uptake is upregulated in omental adipocytes from patients undergoing bariatric surgery for obesity. Int J Obes (Lond) 2005;29(2):196-203
81. Bradbury MW, Berk PD. Lipid metabolism in hepatic steatosis. Clin Liver Dis 2004;8(3):639-671 xi
82. Lee GH, Proenca R, Montez JM, et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996;379(6566):632-635
83. Chua SC Jr, Chung WK, Wu-Peng XS, et al. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 1996;271(5251):994-996
84. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372(6505):425-432
85. Fan X, Bradbury MW, Berk PD. Leptin and insulin modulate nutrient partitioning and weight loss in ob/ob mice through regulation of long-chain fatty acid uptake by adipocytes. J Nutr 2003;133(9):2707-2715
86. Lee Y, Wang MY, Kakuma T, et al. Liporegulation in diet-induced obesity: the antisteatotic role of hyperleptinemia. J Biol Chem 2001;276(8):5629-5635
87. Unger RH. Lipotoxic diseases. Annu Rev Med 2002;53:319-336
88. Unger RH. The physiology of cellular liporegulation. Annu Rev Physiol 2003;65:333-347
89. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269(5223):543-546
90. Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269(5223):540-543
91. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995;269(5223):546-549
92. Remesar X, Rafecas I, Fernandez-Lopez JA, Alemany M. Is leptin an insulin counter-regulatory hormone? FEBS Lett 1997;402(1):9-11
93. Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008;70:537-556
94. Oh-I S, Shimizu H, Sato T, Uehara Y, Okada S, Mori M. Molecular mechanisms associated with leptin resistance: n-3 polyunsaturated fatty acids induce alterations in the tight junction of the brain. Cell Metab 2005;1(5):331-341
95. Listenberger LL, Ory DS, Schaffer JE. Palmitate-induced apoptosis can occur through a ceramide-independent pathway. J Biol Chem 2001;276(18):14890- 14895
96. Unger RH, Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J 2001;15(2):312-321
97. Unger RH. Minireview: weapons of lean body mass destruction - the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003;144(12):5159-5165
98. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003;14(3):281-287
99. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999;401(6748):73-76
100. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004;89(6):2583-2589
101. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993;44:121-131
102. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995;75(3):473-486
103. Dunbar RL, Rader DJ. Slaying the metabolic syndrome: are we battling the Hydra or the Chimera? Minerva Endocrinol 2004;29(3):89-111
104. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002;106(3):286-288
105. Freedland ES. Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. Nutr Metab (Lond) 2004;1(1):12
106. Haynes P, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease in individuals with severe obesity. Clin Liver Dis 2004;8(3):535-547
107. Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8(3):575-594 ix
108. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84(5):1513-1517
109. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002;35(2):367-372
110. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004;15(11):2792- 2800
111. Kerner A, Avizohar O, Sella R, et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005;25(1):193-197
112. Ferroni P, Basili S, Falco A, Davi G. Inflammation, insulin resistance, and obesity. Curr Atheroscler Rep 2004;6(6):424-431
113. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143-3421
114. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Arterioscler Thromb Vasc Biol 2004;24(2):e19-e24
115. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004;24(2):e13-e18
116. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28(9):2289-2304
117. Reaven GM. The individual components of the metabolic syndrome: is there a raison d'etre? J Am Coll Nutr 2007;26(3):191-195
118. Chirieac DV, Chirieac LR, Corsetti JP, Cianci J, Sparks CE, Sparks JD. Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production. Am J Physiol Endocrinol Metab 2000;279(5):E1003-E1011
119. Diehl AM. Lessons from animal models of NASH. Hepatol Res 2005;33(2):138-144
120. Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007;45(6):1366-1374
121. Zhou SL, Gordon RE, Bradbury M, Stump D, Kiang CL, Berk PD. Ethanol up-regulates fatty acid uptake and plasma membrane expression and export of mitochondrial aspartate aminotransferase in HepG2 cells. Hepatology 1998;27(4):1064-1074
122. Berk PD, Zhou S, Bradbury MW. Increased hepatocellular uptake of long chain fatty acids occurs by different mechanisms in fatty livers due to obesity or excess ethanol use, contributing to development of steatohepatitis in both settings. Trans Am Clin Climatol Assoc 2005;116:335-344; discussion 345
123. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114(4):842-845
124. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006;40(suppl 1):S17-S29
125. Merriman RB, Aouizerat BE, Bass NM. Genetic influences in nonalcoholic fatty liver disease. J Clin Gastroenterol 2006;40(suppl 1):S30-S33
126. Mantena SK, King AL, Andringa KK, Eccleston HB, Bailey SM. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med 2008;44(7):1259-1272
127. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008;28:360-369
128. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 2008;28:370-379
129. Charlton M. Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon. Am J Gastroenterol 2007;102(2):409-411
130. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000;105(8):1067-1075
131. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis: II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001;281(5):G1135-G1139
132. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120(5):1183-1192
133. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35(2):373-379
134. Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002;36(2):403-409
135. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;40(1):46-54
136. Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007;46(4):1081-1090
137. Puri P, Mirshahi F, Cheung O, et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008;134(2):568-576
138. Bray GA. Drug treatment of obesity. Rev Endocr Metab Disord 2001;2(4):403-418
139. Klein S, Wadden T, Sugerman HJ. AGA technical review on obesity. Gastroenterology 2002;123(3):882-932
140. Anderson JW, Konz EC, Frederich RC, Wood CL. Longterm weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 2001;74(5):579-584
141. Wadden TA, Foster GD. Behavioral treatment of obesity. Med Clin North Am 2000;84(2):441-461 vii
142. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The Evidence Report. Obes Res 1998;6(suppl 2):51S-209S
143. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995;332(10):621-628
144. Weinsier RL, Nagy TR, Hunter GR, Darnell BE, Hensrud DD, Weiss HL. Do adaptive changes in metabolic rate favor weight regain in weight-reduced individuals? An examination of the set-point theory. Am J Clin Nutr 2000;72(5):1088-1094
145. Mason EE, Ito C. Gastric bypass in obesity. Surg Clin North Am 1967;47(6):1345-1351
146. Hubbard VS, Hall WH. Gastrointestinal surgery for severe obesity. Obes Surg 1991;1(3):257-265
147. Zhao Y, Encinosa W. Agency for Healthcare Research and Quality (AHRQ), Bariatric Surgery Utilization and Outcomes in 1998 and 2004. Statistical Brief # 23. Rockville, MD: Agency or Healthcare Quality and Research; 2007
148. NIDDK Working group on bariatric surgery: executive summary (2002). American Society for Bariatric Surgery. Rationale for the surgical treatment of morbid obesity. Available at: http://www.asbs.org/html/rationale/rationale.html. Accessed April 14, 2008
149. Brolin RE. Gastric bypass. Surg Clin North Am 2001;81(5):1077-1095
150. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995;222(3):339-350; discussion 350-352
151. Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 2002;236(5):554-559
152. Kral JG, Naslund E. Surgical treatment of obesity. Nat Clin Pract Endocrinol Metab 2007;3(8):574-583
153. Elder KA, Wolfe BM. Bariatric surgery: a review of procedures and outcomes. Gastroenterology 2007;132(6):2253-2271
154. Buchwald H. A bariatric surgery algorithm. Obes Surg 2002;12(6):733-746; discussion 747-750
155. Regan J, Selzer DJ, Inabnet WB. Choosing the right laparoscopic bariatric surgical procedure. In: Inabnet WB, DeMaria EJ, Ikramuddin S, eds. Laparoscopic Bariatric Surgery. Philadelphia: Lippincott Williams and Wilkins; 2004:47-54
156. Belle SH, Berk PD, Courcoulas AP, et al. Safety and efficacy of bariatric surgery: longitudinal assessment of bariatric surgery. Surg Obes Relat Dis 2007;3(2):116-126
157. DeMaria EJ, Jamal MK. Laparoscopic adjustable gastric banding: evolving clinical experience. Surg Clin North Am 2005;85(4):773-787 vii
158. Gagner M, Inabnet WB, Pomp A. Laparoscopic sleeve gastrectomy with second stage biliopancreatic diversion and duodenal switch in the superobese. In: Inabnet WB, DeMaria EJ, Ikramuddin S, eds. Laparoscopic Bariatric Surgery. Philadelphia: Lippincott Williams and Wilkins; 2004:143-150
159. Scharf MT, Ahima RS. Gut peptides and other regulators in obesity. Semin Liver Dis 2004;24(4):335-347
160. Murphy KG, Dhillo WS, Bloom SR. Gut peptides in the regulation of food intake and energy homeostasis. Endocr Rev 2006;27(7):719-727
161. Wren AM, Bloom SR. Gut hormones and appetite control. Gastroenterology 2007;132(6):2116-2130
162. Chaudhri OB, Salem V, Murphy KG, Bloom SR. Gastrointestinal satiety signals. Annu Rev Physiol 2008;70:239-255
163. de Fatima Haueisen Sander Diniz M, de Azeredo Passos VM, Diniz MT. Gut-brain communication: how does it stand after bariatric surgery? Curr Opin Clin Nutr Metab Care 2006;9(5):629-636
164. le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006;243(1):108-114
165. le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007;246(5):780-785
166. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86(12):5992
167. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346(21):1623-1630
168. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001;409(6817):194-198
169. Korner J, Inabnet W, Conwell IM, et al. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 2006;14(9):1553-1561
170. Foschi D, Corsi F, Colombo F, et al. Different effects of vertical banded gastroplasty and Roux-en-Y gastric bypass on meal inhibition of ghrelin secretion in morbidly obese patients. J Invest Surg 2008;21(2):77-81
171. Kotidis EV, Koliakos GG, Baltzopoulos VG, Ioannidis KN, Yovos JG, Papavramidis ST. Serum ghrelin, leptin and adiponectin levels before and after weight loss: comparison of three methods of treatment - a prospective study. Obes Surg 2006;16(11):1425-1432
172. Chan JL, Mun EC, Stoyneva V, Mantzoros CS, Goldfine AB. Peptide YY levels are elevated after gastric bypass surgery. Obesity (Silver Spring) 2006;14(2):194-198
173. Brolin RE, Bradley LJ, Taliwal RV. Unsuspected cirrhosis discovered during elective obesity operations. Arch Surg 1998;133(1):84-88
174. Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med 1970;282(15):829-834
175. Marubbio AT Jr, Buchwald H, Schwartz MZ, Varco R. Hepatic lesions of central pericellular fibrosis in morbid obesity, and after jejunoileal bypass. Am J Clin Pathol 1976;66(4):684-691
176. Campbell JM, Hunt TK, Karam JH, Forsham PH. Jejunoileal bypass as a treatment of morbid obesity. Arch Intern Med 1977;137(5):602-610
177. Vyberg M, Ravn V, Andersen B. Pattern of progression in liver injury following jejunoileal bypass for morbid obesity. Liver 1987;7(5):271-276
178. Hocking MP, Duerson MC, O'Leary JP, Woodward ER. Jejunoileal bypass for morbid obesity: late follow-up in 100 cases. N Engl J Med 1983;308(17):995-999
179. Marubbio AT, Rucker RD Jr, Schneider PD, Horstmann JP, Varco RL, Buchwald H. The liver in morbid obesity and following bypass surgery for obesity. Surg Clin North Am 1979;59(6):1079-1093
180. DeWind LT, Payne JH. Intestinal bypass surgery for morbid obesity: long-term results. JAMA 1976;236(20):2298-2301
181. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991;12(2):224-229
182. Drenick EJ, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass: prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 1982;82(3):535-548
183. Siegmund SV, Dooley S, Brenner DA. Molecular mechanisms of alcohol-induced hepatic fibrosis. Dig Dis 2005;23(3-4):264-274
184. Ruiz AG, Casafont F, Crespo J, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of nonalcoholic steatohepatitis. Obes Surg 2007;17(10):1374-1380
185. Meinhardt NG, Souto KE, Ulbrich-Kulczynski JM, Stein AT. Hepatic outcomes after jejunoileal bypass: is there a publication bias? Obes Surg 2006;16(9):1171-1178
186. Wills CE. Long-term follow-up of jejunoileal bypass patients with preoperative cirrhosis of the liver. Obes Surg 1994;4(1):37-39
187. Ranlov I, Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion 1990;47(4):208-214
188. Grimm IS, Schindler W, Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. Am J Gastroenterol 1992;87(6):775-779
189. Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 1995;104(1):23-31
190. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004;39(6):1647-1654
191. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998;22(3):222-226
192. Kral JG, Thung SN, Biron S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004;135(1):48-58
193. Clark JM, Alkhuraishi AR, Solga SF, Alli P, Diehl AM, Magnuson TH. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res 2005;13(7):1180-1186
194. Stratopoulos C, Papakonstantinou A, Terzis I, et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg 2005;15(8):1154-1160
195. Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005;242(4):610-617; discussion 618-620
196. Mottin CC, Moretto M, Padoin AV, et al. Histological behavior of hepatic steatosis in morbidly obese patients after weight loss induced by bariatric surgery. Obes Surg 2005;15(6):788-793
197. de Almeida SR, Rocha PR, Sanches MD, et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg 2006;16(3):270-278
198. Klein S, Mittendorfer B, Eagon JC, et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 2006;130(6):1564-1572
199. Jaskiewicz K, Raczynska S, Rzepko R, Sledzinski Z. Nonalcoholic fatty liver disease treated by gastroplasty. Dig Dis Sci 2006;51(1):21-26
200. Barker KB, Palekar NA, Bowers SP, Goldberg JE, Pulcini JP, Harrison SA. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006;101(2):368-373
201. Mathurin P, Gonzalez F, Kerdraon O, et al. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology 2006;130(6):1617-1624
202. Csendes A, Smok G, Burgos AM. Histological findings in the liver before and after gastric bypass. Obes Surg 2006;16(5):607-611
203. Dixon JB, Bhathal PS, O'Brien PE. Weight loss and nonalcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg 2006;16(10):1278-1286
204. Liu X, Lazenby AJ, Clements RH, Jhala N, Abrams GA. Resolution of nonalcoholic steatohepatits after gastric bypass surgery. Obes Surg 2007;17(4):486-492
205. Furuya CK Jr, de Oliveira CP, de Mello ES, et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol 2007;22(4):510-514
206. Flum DR, Dellinger EP. Impact of gastric bypass operation on survival: a population-based analysis. J Am Coll Surg 2004;199(4):543-551
207. Sampalis JS, Liberman M, Auger S, Christou NV. The impact of weight reduction surgery on health-care costs in morbidly obese patients. Obes Surg 2004;14(7):939-947
208. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357(8):753-761
209. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357(8):741-752
210. Bray GA. The missing link: lose weight, live longer. N Engl J Med 2007;357(8):818-820